Über mich

Weitere Publikationen

Niculescu L, Ruini C, Srour J, Salzer S, Schönbuchner I, von Braunmühl T, Ruzicka T, Hohenleutner U, Giehl KA, Fischer J, Wollenberg A. Tazarotene 0.015% Cream as a Potential Topical Agent for Management of Ichthyosis in Dorfman-Chanarin Syndrome. Acta Derm Venereol. 2019 Mar 1;99(3):345-346.

Sander D, Schröder J, Schönbuchner I, Schreml J, Karrer S, Berneburg M, Schreml S. Erythrodermia Congenitalis Ichthyosiformis Bullosa of Brocq. Case Rep Dermatol. 2016 Jan 30;8(1):19-21.

Hotz A, Oji V, Bourrat E, Jonca N, Mazereeuw-Hautier J, Betz RC, Blume- Peytavi U, Stieler K, Morice-Picard F, Schönbuchner I, Markus S, Schlipf N, Fischer J. Expanding the Clinical and Genetic Spectrum of KRT1, KRT2 and KRT10 Mutations in Keratinopathic Ichthyosis. Acta Derm Venereol. 2016 May;96(4):473-8.

U. Hehr, I. Schönbuchner, B. H. F. Weber. Humangenetische Diagnostik in der frauenärztlichen Praxis. Geburtshilfe Frauenheilkd 2014; 74(10): R55-R73

Schreml S, Weber BH, Schröder J, Siegmund H, Schaller J, Vogt T, Landthaler M, Schönbuchner I, Röcken C, Babilas P. Familial primary localized cutaneous amyloidosis with an oncostatin M receptor-β mutation, Pro694Leu. Clin Exp Dermatol. 2013 Dec;38(8):932-5.

Mavaddat N, ..., Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47.

Antoniou AC, ..., Chenevix-Trench G; CIMBA. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2011 Aug 15;20(16):3304-21.

Mulligan AM, ..., Antoniou AC; Breast Cancer Family Registry; EMBRACE; GEMO Study Collaborators; HEBON; kConFab Investigators; Ontario Cancer Genetics Network; SWE-BRCA; CIMBA. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2011;13(6):R110.

Antoniou AC, ..., Easton DF; CIMBA. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010 Dec 1;70(23):9742-54.

Walker LC, ..., Couch FJ. Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2010;12(6):R102.

Antoniou AC, ..., Chenevix-Trench G; CIMBA. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2009 Nov 15;18(22):4442-56.

Gadzicki D, Wingen LU, Teige B, Horn D, Bosse K, Kreuz F, Goecke T, Schäfer D, Voigtländer T, Fischer B, Froster U, Welling B, Debatin I, Weber BH, Schönbuchner I, Nippert I, Schlegelberger B; German Cancer Aid Consortium on Hereditary Breast and Ovarian Cancer. Communicating BRCA1 and BRCA2 genetic test results. J Clin Oncol. 2006 Jun 20;24(18):2969-70

Preisler-Adams S, Schönbuchner I, Fiebig B, Welling B, Dworniczak B, Weber BH. Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin. Cancer Genet Cytogenet. 2006 Jul 1;168(1):44-9.

Bendig I, Mohr N, Kramer F, Weber BH. Identification of novel TP53 mutations in familial and sporadic cancer cases of German and Swiss origin. Cancer Genet Cytogenet. 2004 Oct 1;154(1):22-6.